World Myasthenia Gravis Market Opportunities Assessed & Forecast in Topical GlobalData Report Available at MarketPublishers.com
16 Sep 2015 • by Natalie Aster
LONDON – Over the past decades, the worldwide myasthenia gravis market has been dominated by short-term and long-term immunosuppressant drugs and acetylcholinesterase inhibitors (AChEIs). During the forecast period, new classes of drugs are projected the come into the market.
The myasthenia gravis market is expected to be driven mainly by the advent of monoclonal antibodies in the upcoming years. The rise in prevalence is set to support the market growth as well as high unmet needs are likely to insure that the market remains interesting in the offing. The largest hindrance to the myasthenia gravis market growth are expected reimbursement difficulties. Additionally, generic drugs and off-label drugs dominate the global myasthenia gravis market, limiting the costs of treatment for patients with an acceptable level of disease control. The biggest unmet needs in myasthenia gravis is a targeted, steroid-sparing therapy. Around 10% of patients are presently refractory to treatment and are in urgent need for novel treatment modalities. Patients presently treated with steroids are also likely to benefit from appropriate additions to the treatment regime.
Topical research report “OpportunityAnalyzer: Myasthenia Gravis - Opportunity Analysis and Forecasts to 2024” prepared by GlobalData provides an exhaustive guide to the myasthenia gravis market. It gives a detailed overview of this chronic autoimmune neuromuscular disease; presents reliable data on annualised market revenue, annual cost of therapy and treatment usage pattern (from 2014) plus forecasts up to 2024. The report provides in-depth market characterisation, limelights key unmet needs, discusses R&D activity, gives an assessment of clinical trials including an analysis of late stage trials, and examines the implications for the therapeutics market. The research publication contains a detailed pipeline overview, specifically focusing on the late-stage pipeline myasthenia gravis drugs with a discussion of emerging trends along with an overview of drugs in earlier clinical studies. The report canvasses the competitive scenario; provides deep insights into key industry restraints and drivers, as well as major challenges to the market growth.
OpportunityAnalyzer: Myasthenia Gravis - Opportunity Analysis and Forecasts to 2024
Published: June, 2015
Price: US$ 9,495.00
More reports by the researcher can be found at GlobalData page.